Carbohydrate Metabolism Disorders in Patients with Pancreas Neuroendocrine Tumors (PNET) Based on Patients from Department of Endocrinology in 2009-2011 Abstract #704

Introduction: Pancreatic Neuroendocrine Tumors (PNET), 80% of which are non-functioning, can be hormonally active.
Aim(s): The valuation of carbohydrate metabolism disorders in patients with PNET and impact of annual somatostatin treatment on carbohydrate metabolism parameters.
Materials and methods: The study included 25 PNET patients (7M/18F), mean age - 63.8 y.o.(±16,8). The groups consisted of eight patients with functioning tumors (F-PNET) (seven insulinomas and one glucagonoma) and 17 patients with NF-PNET. There were 14 patients in stage G1, stage G2-10 and stage G3-1. HbA1C, C-peptide, glucose and insulin concentration levels in OGTT were evaluated in DM-free patients and Chromogranin A with 5-OHIO acid in every patient.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Elżbieta Andrysiak-Mamos

To read results and conclusion, please login ...

Further abstracts you may be interested in

#120 Somatostatin receptors 1-5 expression in a large series of well-differentiated neuroendocrine tumors
Introduction: For their antisecretive and antiproliferative effect somatostatin analogs (SA) have been used in the treatment of neuroendocrine tumors (NETs), based on the expression of somatostatin receptors (sstRs). The potential availability of new SA for the treatment of patients with NETs suggests a better characterization of sstRs.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Paola Loli
#169 Radio guided surgery in neuroendocrine tumours using 68Ga-labeled somatostatin analogs – a pilot study.
Introduction: Radioguided surgery (RGS) is an intraoperative localizing technique for the detection of cancer tissue using tumor-specific radionuclides.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors
Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Chiara Lambertini
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
#657 Correlation of Monoclonal and Polyclonal Somatostatin Receptor (SSTR) 5 Antibodies in Pancreatic Neuroendocrine Tumors
Introduction: For a few years now, highly specific monoclonal antibodies have been available to characterize neuroendocrine tumors for somatostatin-receptor (SSTR) expression.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Daniel Kaemmerer
Authors: Kaemmerer D, Lupp A, Peter L, Fischer E, ...